Redsense is a medical device company that provides an innovative system to detect blood loss during hemodialysis by means of patented fibre optic sensors. It is the company's long-term strategy to expand the use of this technology to new areas, including chronic wound care. As part of this effort, Redsense is now developing a smart wound monitoring system that will measure the physiological parameters relevant to the healing process in real time. The system consists of a disposable and safe sensor layer, low-cost and easily integrated into existing wound dressings, which will be controlled by a microprocessor.

The company will utilize the grant to develop a software module, where sensor data will be processed with the use of AI/ML algorithms. An existing set of simulation data from 400,000 dialysis treatments monitored for blood loss with Redsense's technology will be used to train the algorithms.

"We see machine learning as the most convenient approach to distinguish meaningful information from noise in the signal, and to establish which parameters are the most relevant; it isalso much more cost-efficient in comparison with building a set of expert rules," says Patrik Byhmer, CEO of Redsense Medical AB. 

At the conclusion of the project, the company expects to have developed a proof of concept (PoC) software to control the sensors, and also to have gained valuable indications on the optimal design of the sensor itself. 

"A successful PoC will give us the opportunity to move things one step further. This innovation will target the fast growing market of advanced wound care products. It will also be a game changer for chronic wound patients and healthcare professionals, as it will enable early detection of possible complications, reduce pain and discomfort and provide faster and personalized healing," says Patrik Byhmer.